I was also going to bring up the point that pharmacare can actually promote medication safety. That is not something we've talked about, but it's an important part of the program. I also wanted to share an example that illustrates the point that you were making in your question.
There's a particular class of medication called proton pump inhibitors. They are used to treat GERD or heartburn, and every so often when one of these medications on patent is coming off patent, the drug company that's losing the patent will come up with a biosimilar molecule that's different enough that they can extend their patent but that offers no meaningful clinical benefit. That's the drug they'll go out and market. They'll lobby different insurance plans to cover it, and more often than not, the private insurance plans will say no. Even public drug plans, the ones that many of my low-income patients and seniors access in Ontario, said no, because they use some of the mechanisms that already exist, such as the common drug review, which is part of the process that CADTH employs to make the decision that we're only going to pay for medications that offer cost-effectiveness and meaningful clinical benefit. Otherwise, why are we going to pay for a medication that costs more but offers no added benefit?